AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
48.48
+0.25 (0.52%)
At close: Dec 31, 2025, 4:00 PM EST
48.00
-0.48 (-0.99%)
After-hours: Dec 31, 2025, 6:32 PM EST
AnaptysBio Employees
AnaptysBio had 136 employees as of December 31, 2024. The number of employees increased by 19 or 16.24% compared to the previous year.
Employees
136
Change (1Y)
19
Growth (1Y)
16.24%
Revenue / Employee
$1,246,081
Profits / Employee
-$622,279
Market Cap
1.34B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136 | 19 | 16.24% |
| Dec 31, 2023 | 117 | 21 | 21.88% |
| Dec 31, 2022 | 96 | -6 | -5.88% |
| Dec 31, 2021 | 102 | 8 | 8.51% |
| Dec 31, 2020 | 94 | 5 | 5.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANAB News
- 17 days ago - Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 5 weeks ago - Anaptys Announces Participation in December Investor Conferences - GlobeNewsWire
- 5 weeks ago - AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
- 5 weeks ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
- 5 weeks ago - GSK, AnaptysBio Sue Each Other Over Cancer Drug License - WSJ
- 5 weeks ago - Anaptys Announces $100 Million Stock Repurchase Plan - GlobeNewsWire
- 5 weeks ago - Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary - GlobeNewsWire
- 7 weeks ago - AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement - Seeking Alpha